SOSAFE-GMBH
7.2.2024 09:01:27 CET | Business Wire | Press release
SoSafe, Europe’s leading vendor for security awareness, behavior, and culture change, today announced the appointment of Andrew Rose as its new Chief Security Officer (CSO). With a wealth of experience in the industry, Rose is a highly accomplished cyber security executive with a strong focus on the people-centric aspects of cyber security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240207094549/en/
Andrew Rose appointed as new Chief Security Officer at leading security awareness vendor SoSafe (Photo: Business Wire)
In his role as CSO, Rose will focus on driving SoSafe’s vision to strengthen digital self-defense worldwide and help customers transform their security culture. He’ll also bring hands-on experience, knowledge, and perspective in managing risk and improving cyber security posture across complex enterprises.
Recognized for his outstanding contributions to the field, Rose was awarded the prestigious title of 'European CISO of the Year 2018' at the SC Awards, and has been a part of the CSO30 every year since its inception in 2020. Across his career, Rose has transformed security management for multiple major organizations in the legal, aviation, technology, and finance sectors.
Notably, Rose held the position as Resident CISO at Proofpoint Inc., where he helped customers enhance their security practices, cultivated a community of CISOs and represented the brand externally. Prior to that, he oversaw the cyber security of UK airspace traffic at NATS and managed the secure processing of trillions of pounds in transfers at Vocalink, a Mastercard company. He also worked at Forrester Research, where he was Principal Analyst covering the awareness and culture change space and developed influential models for the security awareness industry. In 2015, when Rose implemented the models he had designed at Forrester, he was awarded ‘UK Awareness Campaign of the Year’ at the UK Cyber Security Awards. Rose also has an established record in the legal sector with over a decade as CISO at 'magic circle' firms Clifford Chance LLP and Allen & Overy LLP.
Niklas Hellemann, Psychologist and CEO of SoSafe, remarked: "Andrew’s expertise is a perfect match for our mission at SoSafe. In an era where AI-powered cyber threats are escalating, Andrew's extensive industry experience is invaluable in leading our efforts to be the global industry leader in fortifying the human aspect of cyber security.”
Rose's decision to join SoSafe was driven by the company's unwavering focus on addressing the critical problem of the underestimated human factor in cyber security. “There is a huge imbalance in focus as the biggest part of security budgets are dedicated to security technology while according to the World Economic Forum, 95% of cyber threats have a human element involved. SoSafe’s commitment to strengthening the human factor, coupled with their innovative use of behavioral science and technology, aligns perfectly with my vision.”
“SoSafe’s approach to security awareness is unique in the industry: Having a CEO with a background in psychology means that the human-centric perspective is deeply rooted in their DNA. They focus on behavioral science to tackle the problem and then use technology to enable the solution”, Rose stated.
By joining SoSafe, Andrew Rose will further strengthen the company's position as a leader in the industry. With his track record of success and commitment to driving secure behavior in organizations, Andrew Rose is poised to make a significant contribution to the company's ongoing mission of strengthening digital self-defense.
About SoSafe
SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by Dr Niklas Hellemann, Lukas Schaefer, and Felix Schuerholz. Today, it serves more than 4500 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team consists of more than 370 employees at seven locations: Cologne (headquarters), Amsterdam, Berlin, Lisbon, London, Munich, and Paris.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207094549/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
